The Latest
Tiziana Life Sciences (TLSA) Reports Positive Phase 2a Clinical Data Exhibiting Positive Clinical Activity with Milciclib Monotherapy in Advanced Sorafenib-refractory or -intolerant Patients with Unresectable or Metastatic Hepatocellular Carcinoma
NEW YORK–(BUSINESS WIRE)– Tiziana Life Sciences plc (TLSA), a biotechnology company focusing…